Gene therapy for spinal muscular atrophy
- PMID: 37423714
- DOI: 10.1136/archdischild-2023-325359
Gene therapy for spinal muscular atrophy
Keywords: Neurology; Paediatrics; Pharmacology; Therapeutics.
Conflict of interest statement
Competing interests: VLG has received consultancy/speaker honoraria from Novartis, Roche, Biogen, PTC Therapeutics, Pfizer and Sarepta Therapeutics. EW has received consultancy/speaker honoraria from Pfizer, Biogen and Novartis. HJ has received consultancy/honoraria from Pfizer.
MeSH terms
LinkOut - more resources
Medical